Clinical trial · Interventional
Endobronchial Ultrasound (EBUS) for Nodal Staging in Esophageal Cancer
NCT01038544CI-TRIAL-00007241CT0003completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is determine if performing endobronchial ultrasound (EBUS) in addition to standard endoscopic ultrasound (EUS) can increase the precision and accuracy of staging esophageal cancer in comparison to EUS alone. The expectation is that EBUS can be used to biopsy lymph nodes that: (1) because of their position in the mediastinum would be inaccessible to EUS, or (2) would be inaccessible due to their position behind the esophageal tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endobronchial Ultrasound (EBUS) | Procedure | — | UNRESOLVED |
| Endoscopic Ultrasound (EUS) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The primary outcome measure will be the accuracy of the combination of EUS and EBUS to correctly diagnose the presence or absence of mediastinal lymph node metastases compared to EUS alone.
- timeFrame
- 6 months intervals
Secondary outcomes (3)
- measure
- The safety of all diagnostic techniques will be evaluated and compared between techniques.
- timeFrame
- 6 months
- measure
- Procedure-related morbidity
- timeFrame
- 6 months
- measure
- Change in treatment plan based on EBUS
- timeFrame
- Study termination
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy proven esophageal cancer * Endoluminal esophageal mass without previous biopsy * Medical suitability for endoscopic procedure * Ability to consent Exclusion Criteria: * Patient on Coumadin (Warfarin) or Plavix (Clopidogrel) with inability to stop medication for 5 days prior to procedure * Anatomy precluding EBUS * Endobronchial tumor * Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.